Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

New Products In Brief

This article was originally published in The Gray Sheet

Executive Summary

Stryker's iVAS kyphoplasty system: Firm's Interventional Spine business launches iVAS minimally invasive, vertebral augmentation system for use in treating vertebral compression fractures (VCFs), Stryker announces April 13. During vertebral augmentation, also known as balloon kyphoplasty, a balloon catheter creates a void in the collapsed vertebra into which bone cement is delivered, creating an internal cast that stabilizes the fracture and alleviates pain in about 90% of patients, Stryker says. According to the firm, about 700,000 VCFs occur per year. Stryker now offers balloon kyphoplasty and vertebroplasty solutions on the same portfolio of "mixer and delivery systems, bone cements and needles," the firm notes, "giving physicians the flexibility to customize their treatment approach based on the type of compression fracture and patient anatomy." One recent study, however, suggests vertebroplasty treatment of spine fractures may have no lasting benefit (1"The Gray Sheet" Aug. 10. 2009)

You may also be interested in...



Stryker Bets $316 Million It Can Invigorate Orthovita's Biologics Biz

Stryker hopes its sales force heft can push Orthovita's line of synthetic orthobiologics into a better growth position while filling important competitive gaps.

Stryker Bets $316 Million It Can Invigorate Orthovita's Biologics Biz

Stryker hopes its sales force heft can push Orthovita's line of synthetic orthobiologics into a better growth position while filling important competitive gaps.

Stryker Wraps Up Last Of FDA Warning Letters, Pledges To Retain QSR Focus

Stryker has resolved the last of four FDA warning letters, but the company maintains its efforts to improve quality systems company-wide will continue

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

MT028765

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel